News
SAVA
20.50
+4.38%
0.86
Weekly Report: what happened at SAVA last week (0415-0419)?
Weekly Report · 19h ago
Noteworthy Tuesday Option Activity: BX, WBD, SAVA
NASDAQ · 6d ago
Weekly Report: what happened at SAVA last week (0408-0412)?
Weekly Report · 04/15 10:34
Redemption Date Announced for Warrants
Monday, May 6, 2024 is the last and final day to exercise the warrants that were previously distributed to shareholders on January 3, 2024. Holders who exercise their warrants will receive 1.5 shares of Cassava Sciences’ common stock per Warrant, for an effective price of approximately $22.00.
Barchart · 04/15 08:20
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
JPMorgan Chase & Co. Shares dipped 5.1% to $185.49 following first-quarter earnings on Friday. PaxMedica, Inc. Shares jumped 143% after the company reported better-than-expected results on Thursday. Rent the Runway shares jumped 162% on Thursday after reporting mixed results.
Benzinga · 04/12 18:47
Analysts’ Top Healthcare Picks: Mainz Biomed B.V. (MYNZ), Century Therapeutics (IPSC)
TipRanks · 04/12 10:20
Weekly Report: what happened at SAVA last week (0401-0405)?
Weekly Report · 04/08 10:38
Weekly Report: what happened at SAVA last week (0325-0329)?
Weekly Report · 04/01 10:37
Cassava Sciences: New Year, Same Game Of Smoke And Mirrors
Cassava Sciences, Inc. Reported $121.1m of cash and a net loss of $97.2m for the year 2023. The company's drug candidate, simufilam, for Alzheimer's disease has not been approved for commercial use by the FDA. Cassava's CEO remains optimistic about the Phase 3 program of its drug candidate for the disease.
Seeking Alpha · 03/25 17:50
Cassava Alzheimer's candidate simufilam clears phase 3 safety review
Cassava Sciences' Alzheimer's candidate simufilam clears phase 3 safety review. Top-line efficacy data for the 12-month study is due later this year. The board is only charged with reviewing safety, not efficacy of the drug. Cassava Sciences is a subsidiary of ETCassava Sciences.
Seeking Alpha · 03/25 15:58
Cassava Sciences’ Alzheimer’s Treatment Shows Promise: A Strong Buy Recommendation
TipRanks · 03/25 14:55
Cassava Sciences Completes Interim Safety Review Of Oral Simufilam On-Going Phase 3 Trials
An independent data and safety monitoring board has recommended both Phase 3 trials of Simufilam continue as planned. Final clinical safety data for oral Simfilam are expected at the end of the Phase 3 program. The DSMB has reviewed the Interim Patient Safety Database for Oral Simafilam.
Benzinga · 03/25 13:14
Weekly Report: what happened at SAVA last week (0318-0322)?
Weekly Report · 03/25 10:39
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
Cassava Sciences, Inc. Has completed another interim safety review of simufilam in on-going Phase 3 clinical trials in patients with Alzheimer's disease. A Data and Safety Monitoring Board recommended both of Cassava Sciences’ studies continue as planned. The company is a biotechnology company focused on Alzheimer’s disease.
Barchart · 03/25 08:13
(SAVA) - Analyzing Cassava Sciences's Short Interest
Cassava Sciences's short percent of float has fallen 3.46% since its last report. The company has 11.76 million shares sold short, which is 29.54% of all regular shares available for trading. Short interest is the number of shares that have been sold short but have not yet been covered.
Benzinga · 03/21 16:30
Weekly Report: what happened at SAVA last week (0311-0315)?
Weekly Report · 03/18 10:38
Cassava Sciences: Where Did All The Mild Alzheimer's Disease Patients Go?
Cassava Sciences' simufilam has little effect on mild Alzheimer's disease patients. The company presented a chart at a conference that did not match the one it presented last year. The drug may be approved for those with pre-Alzheimer's disease. Cassava Sciences has no patients with mild cognitive impairment.
Seeking Alpha · 03/17 13:42
Alzheimer's Drug Trial Results Questioned After 'Damning' FDA Inspection Report
A critical inspection report by the Food and Drug Administration has questioned the credibility of the clinical trial results for an experimental Alzheimer's drug. The drug, simufilam, was developed by a collaborator at the City University of New York. The report highlighted several issues with the drug's clinical trial work.
Benzinga · 03/12 03:51
Boeing, Oracle, Meta Platforms, Cassava Sciences, Tesla: Why These 5 Stocks Are On Investors' Radars Today
The Dow Jones index closed up 0.12% on Monday. Boeing shares fell by 3.02% to close at $192.49. Oracle Corporation and Meta Platforms Inc. Were among the top five trending stocks of the day. The U.S. Stock market presented a mixed performance.
Benzinga · 03/12 02:33
Cassava Sciences again under scrutiny over Alzheimer's drug research
Cassava Sciences under scrutiny over Alzheimer's drug research. A September 2022 US FDA inspection found problems with a lab run by a scientist with ties to Cassava Sciences. The company's Alzheimer's candidate simufilam was flagged with a multitude of issues in the report.
Seeking Alpha · 03/11 23:15
More
Webull provides a variety of real-time SAVA stock news. You can receive the latest news about Cassava Sciences through multiple platforms. This information may help you make smarter investment decisions.
About SAVA
Cassava Sciences, Inc. is a biotechnology company focused on Alzheimer's disease. The Company's science is based on stabilizing, but not removing, a critical protein in the brain. The Company is focused on its product discovery and development efforts on disorders of the nervous system. Its lead therapeutic drug candidate, simufilam, is under clinical evaluation for the proposed treatment of Alzheimer's disease dementia in Phase 3 clinical studies. The Company has two biopharmaceutical assets under development. Its lead therapeutic product candidate, called simufilam, is an oral treatment for Alzheimer's disease dementia. Its lead investigational diagnostic product candidate, called SavaDx, is a way to detect the presence of Alzheimer's disease from a small sample of blood. Simufilam targets an altered form of a protein called filamin A in the Alzheimer's brain. It owns rights to its drug and diagnostic assets and related technologies, without royalty obligations to any third party.